Using NBI and MRI to Improve Treatment for Nasopharyngeal Carcinoma
Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma
This study is testing whether using a special imaging technique with MRI can help improve treatment and quality of life for people with nasopharyngeal cancer during their radiotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chongqing University Cancer Hospital Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06167109 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness and safety of Narrow Band Imaging (NBI) combined with MRI to optimize clinical target volume (CTV) in patients with eccentric nasopharyngeal carcinoma (NPC). Patients are selected based on MRI findings and undergo NBI endoscopy to confirm the diagnosis. They are then randomly assigned to receive either optimized CTV or conventional CTV during radiotherapy. The study aims to compare the incidence of radiotherapy-related adverse events and the quality of life between the two treatment groups.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of eccentric nasopharyngeal carcinoma.
Not a fit: Patients with other types of nasopharyngeal carcinoma or those with significant tumor invasion may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes and reduced side effects for patients with nasopharyngeal carcinoma.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in optimizing treatment for head and neck cancers using advanced imaging techniques.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Males and females ≥18 years of age; 2. ECOG Performance Status 0,1 or 2; 3. Pathologically diagnosed as nasopharyngeal carcinoma; 4. Pretreatment nasopharynx and neck MRI imaging; 5. Nasopharyngeal suspected lesions were examined by NBI endoscopy; 6. Meeting the definition of eccentric NPC with ipsilateral (affected side) staging of T1-4 and contralateral (healthy side) staging of T0; 7. Patients evaluated without contraindications to radiotherapy; 8. Voluntary participation in clinical research, and signed informed consent. Exclusion Criteria: 1. Patients who did not successfully undergo all three examinations (MRI, NBI, and endoscopic biopsy); 2. Other rare pathological types, such as adenocarcinoma; 3. Patients with tumor invasion of the clivus; 4. Patients whose contralateral retropharyngeal lymph nodes met the diagnostic criteria; 5. Invasion of paranasal sinuses (except simple sphenoid invasion).
Where this trial is running
Chongqing, Chongqing Municipality
- Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Ying Wang, Ph.D, M.D. — Chongqing University Cancer Hospital
- Study coordinator: Yuwei Wang, M.M.
- Email: 38664816@qq.com
- Phone: 13436161758
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.